AMRS - Amyris, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.9800
+0.8000 (+19.14%)
As of 3:16PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close4.1800
Open4.3000
Bid5.0200 x 1400
Ask5.0300 x 800
Day's Range4.2500 - 5.1299
52 Week Range1.8700 - 9.2900
Volume6,973,655
Avg. Volume4,240,050
Market Cap381.1M
Beta (3Y Monthly)0.51
PE Ratio (TTM)N/A
EPS (TTM)-3.5220
Earnings DateMay 13, 2019 - May 17, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.00
Trade prices are not sourced from all markets
  • GlobeNewswire22 minutes ago

    SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Amyris, Inc. – AMRS

    Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Amyris, Inc. (AMRS) from March 15, 2018 and March 19, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Amyris investors under the federal securities laws. To join the Amyris class action, go to http://pawarlawgroup.com/cases/amyris-inc/ or call Vik Pawar, Esq.

  • Here's Why Amyris Is Soaring Today
    Motley Fool2 hours ago

    Here's Why Amyris Is Soaring Today

    Another day, another transaction. Is the synthetic biology pioneer better positioned to execute now?

  • ACCESSWIRE2 hours ago

    SHAREHOLDER DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Amyris, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / April 18, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Amyris, Inc. ("Amyris" or "the Company") (NASDAQ: AMRS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between March 15, 2018 and March 19, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before June 3, 2019.

  • Business Wire5 hours ago

    Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amyris, Inc.

    Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming June 3, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Amyris, Inc. (“Amyris” or the “Company”) (NASDAQ: AMRS) investors who purchased securities between March 15, 2018, and March 19, 2019, inclusive (the “Class Period”). If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. On this news, Amyris’ share price fell $0.78, or nearly 20% to close at $3.10 per share on March 20, 2019, thereby injuring investors.

  • GlobeNewswire7 hours ago

    Amyris Completes Sale of Vitamin E Royalty to DSM

    Amyris, Inc. (AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today announced the sale of its Vitamin E royalty agreement to Koninklijke DSM N.V. (Royal DSM) (DSM.AS). This agreement assigns Amyris’s rights to Vitamin E royalties to DSM in exchange for total consideration of approximately $57 million. In addition, DSM and Amyris have agreed to a further manufacturing cooperation for Amyris products at DSM’s Brotas facility that provides additional capacity and lower cost of goods sold with an expected approximate aggregate benefit of $30–$40 million over the next three years.

  • Business Wire18 hours ago

    INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Amyris, Inc. Investors (AMRS)

    Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Amyris, Inc. (“Amyris” or the “Company”) (NASDAQ: AMRS) securities between March 15, 2018, and March 19, 2019, inclusive (the “Class Period”). Amyris investors have until June 3, 2019 to file a lead plaintiff motion. Investors suffering losses on their Amyris investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.

  • GlobeNewswireyesterday

    INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Amyris, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Amyris, Inc. (“Amyris” or “the Company”) (NASDAQ: AMRS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

  • Business Wire2 days ago

    Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against Amyris, Inc.

    The law firm of Kessler Topaz Meltzer & Check, LLP reminds that an investor securities fraud class action lawsuit has been filed against Amyris, Inc. (AMRS) (“Amyris”) on behalf of purchasers of Amyris securities between March 15, 2018 and March 19, 2019, inclusive (the “Class Period”). Amyris investors who purchased securities during the Class Period may, no later than June 3, 2019, seek to be appointed as a lead plaintiff representative of the class. Investors who wish to discuss this securities fraud class action lawsuit or request additional information about this litigation are encouraged to contact Kessler Topaz Meltzer & Check attorneys James Maro, Jr. or Adrienne Bell at (888) 299-7706 (toll free) or online at: www.ktmc.com/amyris-securities-class-action.

  • ACCESSWIRE2 days ago

    IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Amyris, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / April 16, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Amyris, Inc. ("Amyris" or "the Company") (NASDAQ: AMRS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between March 15, 2018 and March 19, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before June 3, 2019.

  • GlobeNewswire2 days ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amyris, Inc. – AMRS

    Pomerantz LLP is investigating claims on behalf of investors of Amyris, Inc.  (“Amyris” or the “Company”) (NASDAQ: AMRS).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. On this news, Amyris’s stock price fell $0.78 per share, or 20.10%, to close at $3.10 per share on March 20, 2019.

  • ACCESSWIRE2 days ago

    LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Amyris, Inc. To Contact The Firm

    NEW YORK, NY / ACCESSWIRE / April 16, 2019 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Amyris, Inc. (''Amyris'' or the ''Company'') (NASDAQ: AMRS) of the June 3, ...

  • GlobeNewswire2 days ago

    Amyris Repays in Cash April 2019 Convertible Note Debt

    Amyris, Inc. (AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today announced that it has repaid in full the principal amount of its 9.5% convertible notes due April 2019. The notes were paid down with cash from a previously noted business transaction as well as the net proceeds of an equity investment from Foris Ventures, a board member-affiliated long-term investor in Amyris. “We are pleased to have completed this critical step in our efforts to reduce company debt and the complexity of our balance sheet,” said John Melo, Amyris President and CEO.

  • PR Newswire3 days ago

    Investor Alert: Kaplan Fox Investigates Amyris, Inc.

    A complaint has been filed in the United States District Court for the Southern District of New York against the Company and certain executives on behalf of investors that purchased Amyris securities. The complaint alleges that, on November 13, 2018, Amyris reported poor financial results, which it attributed to the "volatility of the Vitamin E market."  Following this news, the price of Amyris' shares fell $1.76 per share, or nearly 30%, to close at $4.14 per share on November 14, 2018. Then, on March 19, 2019, after the market closed, Amyris disclosed that it would be unable to timely file its annual report due to "significant time and resources that were devoted to the accounting for and disclosure of the significant transactions with Koninklijke DSM N.V. that closed in November 2018." Amyris also disclosed that it "is in the process of completing its evaluation of internal control over financial reporting and may have further deficiencies to report."  Following this news, Amyris' shares fell $0.78 per share, about 20%, to close at $3.10 per share on March 20, 2019.

  • ACCESSWIRE3 days ago

    INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Amyris, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / April 15, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Amyris, Inc. ("Amyris" or "the Company") (NASDAQ: AMRS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between March 15, 2018 and March 19, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before June 3, 2019.

  • Business Wire3 days ago

    EQUITY ALERT: Rosen Law Firm Reminds Investors of Amyris, Inc. of Important Deadline in Securities Class Action; Encourages Investors with Over $100K in Losses to Contact the Firm – AMRS

    Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Amyris, Inc. (AMRS) from March 15, 2018 and March 19, 2019, inclusive (the “Class Period”) of the important June 3, 2019 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Amyris investors under the federal securities laws. To join the Amyris class action, go to http://www.rosenlegal.com/cases-register-1550.html or call Phillip Kim, Esq.

  • Here's Why Amyris Jumped as Much as 28.9% Today
    Motley Fool3 days ago

    Here's Why Amyris Jumped as Much as 28.9% Today

    The business received a small lifeline from one of its largest shareholders.

  • GlobeNewswire3 days ago

    Amyris Provides Update on Resolution of April 2019 Convertible Note Maturity

    Amyris, Inc. (AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today announced that it has been working diligently to resolve its 9.5% convertible notes due April 2019 and plans to repay the notes with cash from a business transaction as well as the net proceeds of a planned equity investment from Foris Ventures, a board member-affiliated long-term investor in Amyris. The planned equity investment from Foris Ventures, an entity affiliated with Amyris board member, John Doerr (of Kleiner Perkins Caufield & Byers), is anticipated to provide a portion of the cash needed to satisfy the notes, with the remainder required to retire the debt expected to come through a business transaction.

  • ACCESSWIRE4 days ago

    SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Amyris, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / April 14, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Amyris, Inc. ("Amyris" or "the Company") (NASDAQ: AMRS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between March 15, 2018 and March 19, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before June 3, 2019.

  • GlobeNewswire5 days ago

    INVESTOR ALERT: Kaskela Law LLC Announces Important Shareholder Class Action Lawsuit Deadlines – CORT, HCSG, ARA and AMRS

    Kaskela Law LLC announces that shareholder class action lawsuits have been filed against Corcept Therapeutics Incorporated (CORT), Healthcare Services Group, Inc. (HCSG), American Renal Associates Holdings, Inc. (ARA) and Amyris, Inc. (Nasdaq: AMRS).  Additional information about these class actions lawsuits, including important deadlines in the actions, may be found below.

  • GlobeNewswire6 days ago

    AMYRIS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Amyris, Inc. - AMRS

    Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 3, 2019 to file lead plaintiff applications in a securities class action lawsuit against Amyris, Inc. (AMRS), if they purchased the Company’s securities between March 15, 2018 and March 19, 2019, inclusive (the “Class Period”).  This action is pending in the United States District Court for the Northern District of California.

  • Business Wire6 days ago

    IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Amyris, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Amyris, Inc. (“Amyris” or “the Company”) (NASDAQ: AMRS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between March 15, 2018 and March 19, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before June 3, 2019. We also encourage you to contact Brian Schall, or Sherin Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge.

  • Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Filed Against Amyris, Inc. - AMRS
    PR Newswire6 days ago

    Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Filed Against Amyris, Inc. - AMRS

    RADNOR, Pa., April 12, 2019 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP alerts investors that a securities fraud class action lawsuit has been filed against Amyris, Inc. (Nasdaq:  AMRS) ("Amyris") on behalf of purchasers of Amyris securities between March 15, 2018 and March 19, 2019, inclusive (the "Class Period"). Investors who purchased Amyris securities during the Class Period may, no later than June 3, 2019, seek to be appointed as a lead plaintiff representative of the class.